← All trials
NCT06443255
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2024
- Primary completion
- Aug 27, 2024
- Completion date
- Aug 27, 2024
- First posted
- Jun 5, 2024
- Last posted
- Sep 27, 2024
- Enrollment
- 16
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenOfficial
- University of CopenhagenSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.